TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28764836

Group type: EXPERIMENTAL
Intervention: Long-term aspirin treatment cessation before surgery
Number of subjects: 805

Group type: COMPARATOR
Intervention: Prior PCI with stent implantation
Number of subjects: 805

Group type: COMPARATOR
Intervention: Previous discontinuation of aspirin treatment
Number of subjects: 805

Group type: COMPARATOR
Intervention: Risk of bleeding into a closed space
Number of subjects: 805

Group type: COMPARATOR
Intervention: Unawareness of the reason for aspirin use
Number of subjects: 805

Group type: COMPARATOR
Intervention: Preoperative consultation with anesthesiologist <2 days before surgery
Number of subjects: 805
Study: 28765146

Group type: EXPERIMENTAL
Intervention: Heidelberg Spectralis spectral domain-optical coherence tomography (SD-OCT) device
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Heidelberg Spectralis OCT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SD-OCT/SLO imaging
Number of subjects: 32
Study: 28765502

Group type: EXPERIMENTAL
Intervention: Neoadjuvant 5-fluorouracil (5-FU) 225 mg/m², oxaliplatin, and lapatinib in combination with radiation therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Neoadjuvant 5-fluorouracil (5-FU) in combination with radiation therapy
Number of subjects: 12
Study: 28766094

Group type: EXPERIMENTAL
Intervention: Postpartum illnesses (including uterine prolapse, urinary tract infection, stress related incontinence, headache, convulsions, night blindness, anemia, pneumonia, gastroenteritis, hepatobiliary disease)
Number of subjects: 39000
Study: 28766267

Group type: EXPERIMENTAL
Intervention: Gastric bypass (GBP)
Number of subjects: 4047

Group type: EXPERIMENTAL
Intervention: Vertical banded gastroplasty (VBG)
Number of subjects: 4047

Group type: COMPARATOR
Intervention: Obese non-operated controls (OB-controls)
Number of subjects: 4047

Group type: COMPARATOR
Intervention: MONICA-controls
Number of subjects: 4047
Study: 28766459

Group type: EXPERIMENTAL
Intervention: Cognitive Difficulties Scale (CDS) total score
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cognitive Difficulties Scale (CDS) praxis subscale
Number of subjects: 95
Study: 28766535

Group type: EXPERIMENTAL
Intervention: ALL-2009 protocol (non-intensive, continuous cytotoxic treatment)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: ALL-2009 protocol
Number of subjects: 194
Study: 28767349

Group type: EXPERIMENTAL
Intervention: IdeS
Number of subjects: 25
Study: 28767456

Group type: EXPERIMENTAL
Intervention: Continuous regional anaesthesia (epidural or peripheral nerve block)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Single shot peripheral nerve block
Number of subjects: 563

Group type: COMPARATOR
Intervention: No regional anaesthesia
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Continuous regional anaesthesia
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Higher NRS score at 1 month, younger age, history of anxiety or depression, pro-inflammatory status, higher BMI, lower ASA physical status
Number of subjects: 563
Study: 28767463

Group type: EXPERIMENTAL
Intervention: Adenoma bulk (≥10 mm, 4th quartile)
Number of subjects: 1948

Group type: COMPARATOR
Intervention: Conventional paradigm (high-risk baseline findings: ≥3 adenomas, large adenomas (≥1 cm), or adenomas with villous components or high-grade dysplasia)
Number of subjects: 1948

Group type: EXPERIMENTAL
Intervention: Adenoma bulk (as a continuous variable)
Number of subjects: 1948
Study: 28768073

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sleep diary
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Actigraphy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Polysomnographic nap
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overall sleep problems
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hypersomnia conditions
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) risk
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Restless legs syndrome
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cataplexy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Comorbid PTSD
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Older participants and those with higher aggression, anxiety or depression
Number of subjects: 71
Study: 28768075

Group type: COMPARATOR
Intervention: mTBI
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: mTBI÷PTSD
Number of subjects: 71
Study: 28768072

Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) assessment via 24-hour ambulatory electrocardiography; segments included sleep, wakefulness, exercise, standing still.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abnormal Sharpened Romberg Test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathological nystagmus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased sympathetic modulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased Pittsburgh Sleep Quality Index scores
Number of subjects: 0
Study: 28768493

Group type: EXPERIMENTAL
Intervention: Supportive text messages (twice-daily for 3 months)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (single text message every fortnight)
Number of subjects: 73
Study: 28768612

Group type: EXPERIMENTAL
Intervention: Mobile phone-based intervention (Fitbit Flex, online educational program, biweekly text messages)
Number of subjects: 40
Study: 28768652

Group type: EXPERIMENTAL
Intervention: Nut and peanut butter consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no nut and peanut butter consumption)
Number of subjects: 0
Study: 28768681

Group type: EXPERIMENTAL
Intervention: CALM therapy
Number of subjects: 17
Study: 28768756

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg plus aspirin 325 mg (loading dose) followed by ticagrelor 90 mg BID plus aspirin 81 mg QD (maintenance therapy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Concentrated platelets supplementation (0%, 25%, 50%, 75%)
Number of subjects: 20
Study: 28768758

Group type: EXPERIMENTAL
Intervention: Low Endothelial Shear Stress (ESS <1 Pa)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Higher Endothelial Shear Stress (ESS ≥1 Pa)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low ESS
Number of subjects: 20
Study: 28768799

Group type: EXPERIMENTAL
Intervention: SAH patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Neurologically healthy patients
Number of subjects: 37
Study: 28768822

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (1.0 g/kg every 3 weeks for up to 52 weeks)
Number of subjects: 49
Study: 28768847

Group type: EXPERIMENTAL
Intervention: Males with sensory-motor polyneuropathy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Older males
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Older females
Number of subjects: 160

Group type: COMPARATOR
Intervention: Males and females
Number of subjects: 160
Study: 28768906

Group type: EXPERIMENTAL
Intervention: Fasted state (after 24 hours fasting)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Satiety state
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Physiological hunger
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ghrelin signaling
Number of subjects: 23
Study: 28769925

Group type: EXPERIMENTAL
Intervention: RO5459072, a small molecule inhibitor of Cathepsin S
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28769985

Group type: EXPERIMENTAL
Intervention: Integrative Korean medicine treatment
Number of subjects: 505
Study: 28770037

Group type: EXPERIMENTAL
Intervention: Unaffected siblings of ASD probands (AS)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Unaffected siblings of AS probands
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Unaffected siblings of autism probands
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Stereotyped behaviors
Number of subjects: 199

Group type: COMPARATOR
Intervention: Typically developing controls (TD)
Number of subjects: 199
Study: 28770094

Group type: EXPERIMENTAL
Intervention: Zinc protoporphyrin (ZPP) combined with haemoglobin concentration
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Zinc protoporphyrin (ZPP) alone
Number of subjects: 338

Group type: COMPARATOR
Intervention: Haemoglobin concentration alone
Number of subjects: 338
Study: 28770096

Group type: EXPERIMENTAL
Intervention: BELA-P-k questionnaire
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Parkinson Disease Questionnaire -39 (PDQ39)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Unified Parkinson's Disease Rating Scale (UPDRS)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Frontal Assessment Battery (FAB)
Number of subjects: 202
Study: 28770108

Group type: EXPERIMENTAL
Intervention: Ketorolac with local anesthesia
Number of subjects: 59

Group type: COMPARATOR
Intervention: Local anesthesia alone (Control)
Number of subjects: 59
Study: 28770254

Group type: EXPERIMENTAL
Intervention: FEMBraces
Number of subjects: 48

Group type: COMPARATOR
Intervention: CtrlBraces
Number of subjects: 48
Study: 28770322

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Placebo (masked)
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Metformin (continued in DPPOS)
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3234
Study: 28770408

Group type: EXPERIMENTAL
Intervention: Radium-223 (55 kBq/kg, intravenously) in a 4-week cycle for six cycles
Number of subjects: 49
Study: 28770420

Group type: EXPERIMENTAL
Intervention: DMF 240 mg twice daily
Number of subjects: 769

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 769
Study: 28770543

Group type: EXPERIMENTAL
Intervention: Virtual-reality-based neurocognitive stimulation sessions (20-min daily sessions)
Number of subjects: 20
Study: 28771388

Group type: EXPERIMENTAL
Intervention: Single unit porcelain-fused-to-metal (PFM) crowns (SCs)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3- to 4-unit PFM fixed dental prostheses (FDPs)
Number of subjects: 120
Study: 28771392

Group type: EXPERIMENTAL
Intervention: Comprehensive battery of assessments for auditory and vestibular function
Number of subjects: 71
Study: 28771673

Group type: EXPERIMENTAL
Intervention: Single-agent lenalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Investigator's choice single-agent therapy
Number of subjects: 0
Study: 28771889

Group type: EXPERIMENTAL
Intervention: Pralatrexate, given i.v. weekly for 6 weeks of a 7-week cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent vitamin B, given alongside pralatrexate
Number of subjects: 0
Study: 28772110

Group type: EXPERIMENTAL
Intervention: Compensated Leydig cell dysfunction
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Uncompensated Leydig cell dysfunction
Number of subjects: 158

Group type: COMPARATOR
Intervention: Leydig cell dysfunction (both compensated and uncompensated)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Total testosterone
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Luteinising hormone (LH)
Number of subjects: 158
Study: 28772306

Group type: EXPERIMENTAL
Intervention: Lung adenocarcinoma treatment, specific intervention details not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, specific details not available.
Number of subjects: 0
Study: 28774194

Group type: EXPERIMENTAL
Intervention: Risk factors for alcohol use disorder (family history of alcoholism, male sex, impulsivity)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: All three risk factors present
Number of subjects: 159
Study: 28774271

Group type: EXPERIMENTAL
Intervention: Malay version of the Brief Illness Perception Questionnaire (MBIPQ)
Number of subjects: 312
Study: 28774277

Group type: EXPERIMENTAL
Intervention: Genomic variations in anthracycline metabolism and myocardial response to injury
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Existing and novel biomarkers
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Echocardiographic and cardiac magnetic resonance (CMR) imaging parameters
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Integrated risk-prediction model
Number of subjects: 1125
Study: 28774338

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 125 mg/m²
Number of subjects: 52
Study: 28775115

Group type: EXPERIMENTAL
Intervention: Concentric hypertrophy
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 1282
Study: 28775134

Group type: EXPERIMENTAL
Intervention: Prothrombin time (PT) for rivaroxaban
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Prothrombin time (PT) for apixaban
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Activated partial thromboplastin time (aPTT) for dabigatran
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Thrombin time (TT) for dabigatran
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Reagent-specific PT and aPTT cutoffs
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Thrombin time (TT) cutoff for dabigatran
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Global coagulation tests (normal results)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Reagent-specific cutoffs for global coagulation tests
Number of subjects: 96
Study: 28775185

Group type: EXPERIMENTAL
Intervention: Continuous ECG monitoring during a marathon race
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: High-sensitive troponin T measurement
Number of subjects: 109
Study: 28775244

Group type: EXPERIMENTAL
Intervention: Exhaled breath condensate (EBC) analysis in IPF patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 28775245

Group type: EXPERIMENTAL
Intervention: Nine volatile organic compounds (VOCs) identified in exhaled breath of sarcoidosis patients; accuracy of prediction: 79.4%.
Number of subjects: 87

Group type: COMPARATOR
Intervention: New prediction model for external validation of VOCs; accuracy of prediction: 74%.
Number of subjects: 87
Study: 28775741

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study: 28775900

Group type: EXPERIMENTAL
Intervention: CS-PFP 10
Number of subjects: 0
Study: 28776147

Group type: EXPERIMENTAL
Intervention: Youth with DBDs
Number of subjects: 31

Group type: COMPARATOR
Intervention: Typically developing youth
Number of subjects: 31
Study: 28776320

Group type: EXPERIMENTAL
Intervention: New Medicine Service (NMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal Practice
Number of subjects: 0
Study: 28776448

Group type: EXPERIMENTAL
Intervention: PNPLA3 rs738409
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Gene set enrichment analysis
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Ingenuity Pathway Analysis
Number of subjects: 183
Study: 28776718

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 179

Group type: COMPARATOR
Intervention: CMT (continued medical therapy)
Number of subjects: 179
Study: 28776876

Group type: EXPERIMENTAL
Intervention: Mogamulizumab (defucosylated anti-CCR4 monoclonal antibody)
Number of subjects: 39
Study: 28777005

Group type: EXPERIMENTAL
Intervention: Risk scoring for two-year all-cause mortality risk
Number of subjects: 23489

Group type: EXPERIMENTAL
Intervention: Identified independent mortality predictors
Number of subjects: 23489

Group type: EXPERIMENTAL
Intervention: Developed risk-scoring system
Number of subjects: 23489
Study: 28777025

Group type: EXPERIMENTAL
Intervention: Red-light excitation of protoporphyrin IX (PpIX) fluorescence
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional blue-light fluorescence
Number of subjects: 29
Study: 28777755

Group type: EXPERIMENTAL
Intervention: ADS-5102 (amantadine) 274 mg once daily at bedtime
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo (previous studies)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: ADS-5102 (previous studies)
Number of subjects: 223
Study: 28778175

Group type: EXPERIMENTAL
Intervention: Dual-diagnosis motivational interviewing (DDMI) and integrated group therapy (IGT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study: 28778282

Group type: EXPERIMENTAL
Intervention: Women with PCOS (study group)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Women with hyperandrogenic PCOS (n = 76)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Women with normoandrogenic PCOS (n = 97)
Number of subjects: 188
Study: 28778448

Group type: EXPERIMENTAL
Intervention: PF-00547659 anti-MAdCAM-1 therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal intrathecal leukocyte cell number and composition
Number of subjects: 0
Study: 28778554

Group type: EXPERIMENTAL
Intervention: Integrated Care for patients with psychotic disorders (treatment for ≥4 years)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Patients with somatic comorbidity (SC)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Patients with and without comorbidity
Number of subjects: 187
Study: 28778611

Group type: COMPARATOR
Intervention: Complete vaccination cohort (2 doses of RV1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incomplete vaccination cohort (1 dose of RV1)
Number of subjects: 0
Study: 28778612

Group type: EXPERIMENTAL
Intervention: Prior influenza vaccination
Number of subjects: 141

Group type: COMPARATOR
Intervention: No prior influenza vaccination
Number of subjects: 141
Study: 28778843

Group type: EXPERIMENTAL
Intervention: Usual care plus daily text message reminders for medication adherence
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Usual care plus 4 daily text messages for exercise adherence
Number of subjects: 84
Study: 28778849

Group type: EXPERIMENTAL
Intervention: Simulation-based training (SBT) curriculum of non-technical skills (NTS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Interactive didactic sessions on colonoscopy theory and SBT
Number of subjects: 42
Study: 28778946

Group type: EXPERIMENTAL
Intervention: Subcutaneous electrocardiographic monitors (St. Jude CONFIRM-AF) implanted in patients
Number of subjects: 256
Study: 28779015

Group type: EXPERIMENTAL
Intervention: Genetic risk score based on 28 variants
Number of subjects: 203

Group type: COMPARATOR
Intervention: Conventional risk score alone
Number of subjects: 203
Study: 28779027

Group type: EXPERIMENTAL
Intervention: 14-day gluten challenge with 5.7 grams per oral gluten daily
Number of subjects: 20
Study: 28779469

Group type: EXPERIMENTAL
Intervention: Maladaptive coping strategies and locus of control (attributed to other people)
Number of subjects: 172

Group type: COMPARATOR
Intervention: COPD severity, demographics, and depressive symptoms
Number of subjects: 172
Study: 28780030

Group type: EXPERIMENTAL
Intervention: Lutonix 035 drug-coated balloon (DCB)
Number of subjects: 691
Study: 28780401

Group type: EXPERIMENTAL
Intervention: Task-concurrent functional connectivity dynamics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resting-state functional connectivity
Number of subjects: 0
Study: 28780554

Group type: EXPERIMENTAL
Intervention: Age at stroke onset
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Functional dependency at discharge
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Prestroke PA
Number of subjects: 77
Study: 28780579

Group type: EXPERIMENTAL
Intervention: CKD stage 3B
Number of subjects: 9270

Group type: EXPERIMENTAL
Intervention: Dialysis
Number of subjects: 9270

Group type: EXPERIMENTAL
Intervention: Non-fatal major atherosclerotic event
Number of subjects: 9270
Study: 28780741

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 140770

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 140770
Study: 28780910

Group type: EXPERIMENTAL
Intervention: Collaborative dementia care management intervention
Number of subjects: 446
Study: 28780990

Group type: EXPERIMENTAL
Intervention: RBC folate
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Methylmalonic acid (MMA)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Homocysteine
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Serum folate
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: BMI and homocysteine
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: BMI and MMA
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Age and RBC folate
Number of subjects: 278
Study: 28780991

Group type: EXPERIMENTAL
Intervention: Misreporting identification using fixed cut-offs for the ratio of reported energy intake and estimated energy requirement.
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Over-reporting
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Under-reporting
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Mean values for cut-offs in children ≤12 months
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Mean values for cut-offs in children >12 months
Number of subjects: 1199
Study: 28782982

Group type: EXPERIMENTAL
Intervention: Polysomnography
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Dysfunctional Beliefs and Attitudes About Sleep (DBAS) questionnaire
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: DBAS scores by sex
Number of subjects: 87
Study: 28784130

Group type: EXPERIMENTAL
Intervention: Electronic clinical decision support system
Number of subjects: 6
Study: 28784441

Group type: EXPERIMENTAL
Intervention: Trans-femoral TAVI with balloon post-dilation
Number of subjects: 985

Group type: COMPARATOR
Intervention: Trans-femoral TAVI without balloon post-dilation
Number of subjects: 985
Study: 28784586

Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Number of subjects: 0
Study: 28784593

Group type: EXPERIMENTAL
Intervention: Domiciliary VR-based therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (home-based occupational therapy)
Number of subjects: 35
Study: 28784598

Group type: EXPERIMENTAL
Intervention: Vorinostat (100 mg twice daily) started on day -10 and continued through day +100 post-HCT with tacrolimus and methotrexate for GVHD prophylaxis.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Vorinostat (100 mg twice daily) with tacrolimus and methotrexate.
Number of subjects: 37